Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01957709 · ClinicalTrials.gov registry record · Early Phase 1
Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma
A Early Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
NCT01957709 is a Early Phase 1 study that was terminated before completion, run by Fred Hutchinson Cancer Center. The registered enrollment target is 8 participants.
The verdict
NCT01957709, a Early Phase 1 study, was terminated before completion, sponsored by Fred Hutchinson Cancer Center.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This pilot clinical trial studies the effect of recombinant interferon gamma on tissue in treating patients with soft tissue sarcoma. Interferon gamma may interfere with the growth of tumor cells.
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Recombinant Interferon Gamma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2013-09-25 |
| Est. Completion | 2018-06-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01957709
The ClinicalTrials.gov registry entry for NCT01957709 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01957709 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01957709 about?
NCT01957709 is a clinical study titled "Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma". This pilot clinical trial studies the effect of recombinant interferon gamma on tissue in treating patients with soft tissue sarcoma. Interferon gamma may interfere with the growth of tumor cells.
What is the current status of trial NCT01957709?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2013-09-25. Estimated completion is 2018-06-01.
What interventions are being tested in trial NCT01957709?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Recombinant Interferon Gamma (BIOLOGICAL).
Who is sponsoring clinical trial NCT01957709?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.